The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | Bemarituzumab in solid tumors

Name: Bemarituzumab in solid tumors
Uploaded: 2020-07-06T00:00:00Z
Duration: 4 min 6 s
Description: Daniel Catenacci, MD, University of Chicago, Chicago, IL, describes a Phase Ib escalation and expansion study of bemarituzumab, an anti-FGFR2 monoclonal antibody, in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Daniel Catenacci • 6 Jul 2020

ESMO WCGIC 2020

Gastroesophageal Cancer Gastrointestinal Cancer General Antibodies Bemarituzumab

Daniel Catenacci, MD, University of Chicago, Chicago, IL, describes a Phase Ib escalation and expansion study of bemarituzumab, an anti-FGFR2 monoclonal antibody, in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).